ResMed Company Insiders
RMD Stock | USD 249.56 5.78 2.37% |
ResMed's insiders are aggressively selling. The analysis of insiders' sentiment of trading ResMed Inc stock suggests that all insiders are panicking at this time. ResMed employs about 34 people. The company is managed by 34 executives with a total tenure of roughly 155 years, averaging almost 4.0 years of service per executive, having 1.0 employees per reported executive.
Michael Farrell CEO Chief Executive Officer, Director |
Peter Farrell Chairman Non-Executive Chairman of the Board |
ResMed's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-22 | Justin Leong | Disposed 6160 @ 243.09 | View | ||
2024-11-12 | Witte Jan De | Disposed 796 @ 248.81 | View | ||
2024-11-06 | Peter C Farrell | Disposed 2000 @ 248.74 | View | ||
2024-11-01 | Michael J Rider | Disposed 69 @ 242 | View | ||
2024-10-11 | Kaushik Ghoshal | Disposed 4260 @ 238.48 | View | ||
2024-10-08 | Brett Sandercock | Disposed 1000 @ 233.47 | View | ||
2024-10-07 | Michael J Farrell | Disposed 14683 @ 231.91 | View | ||
2024-10-02 | Peter C Farrell | Disposed 2000 @ 237.2 | View | ||
2024-09-12 | Kaushik Ghoshal | Disposed 5000 @ 252.56 | View | ||
2024-09-09 | Brett Sandercock | Disposed 1000 @ 246.42 | View | ||
2024-09-04 | Peter C Farrell | Disposed 2000 @ 239.9 | View | ||
2024-08-20 | Michael J Rider | Disposed 882 @ 231 | View | ||
2024-08-08 | Brett Sandercock | Disposed 1000 @ 212.16 | View | ||
2024-08-07 | Michael J Farrell | Disposed 14683 @ 214.25 | View | ||
2024-08-05 | Justin Leong | Disposed 48000 @ 217.07 | View | ||
2024-07-08 | Michael J Farrell | Disposed 14683 @ 192.97 | View | ||
2024-06-10 | Brett Sandercock | Disposed 1000 @ 209.81 | View |
Monitoring ResMed's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ResMed |
ResMed's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with ResMed's future performance. Based on our forecasts, it is anticipated that ResMed will maintain a workforce of about 230 employees by December 2024.ResMed's latest congressional trading
Congressional trading in companies like ResMed Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in ResMed by those in governmental positions are based on the same information available to the general public.
2024-06-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2024-06-13 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2023-11-16 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
2023-11-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify |
ResMed Management Team Effectiveness
The company has Return on Asset of 0.1327 % which means that on every $100 spent on assets, it made $0.1327 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2357 %, implying that it generated $0.2357 on every 100 dollars invested. ResMed's management efficiency ratios could be used to measure how well ResMed manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.30, whereas Return On Capital Employed is forecasted to decline to 0.14. At present, ResMed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 482.8 M, whereas Net Tangible Assets are forecasted to decline to about 632.7 M.The current year's Common Stock Shares Outstanding is expected to grow to about 147.7 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 1.1 B
ResMed Workforce Comparison
ResMed Inc is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 226,296. ResMed adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
ResMed Profit Margins
The company has Net Profit Margin of 0.23 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.32 %, which entails that for every 100 dollars of revenue, it generated $0.32 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.67 | 0.5667 |
|
| |||||
Net Profit Margin | 0.13 | 0.2179 |
|
| |||||
Operating Profit Margin | 0.16 | 0.2817 |
|
| |||||
Pretax Profit Margin | 0.18 | 0.27 |
|
| |||||
Return On Assets | 0.096 | 0.1486 |
|
| |||||
Return On Equity | 0.14 | 0.2099 |
|
|
ResMed Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ResMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on ResMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ResMed insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.56 | 14 | 25 | 53,543 | 96,782 |
2024-09-01 | 1.0 | 18 | 18 | 114,285 | 169,894 |
2024-06-01 | 0.2857 | 4 | 14 | 41,366 | 154,265 |
2023-12-01 | 0.6071 | 17 | 28 | 146,813 | 49,243 |
2023-09-01 | 0.6429 | 9 | 14 | 43,273 | 38,005 |
2023-06-01 | 0.1579 | 3 | 19 | 17,025 | 75,150 |
2023-03-01 | 0.1765 | 3 | 17 | 17,025 | 60,563 |
2022-12-01 | 0.6889 | 31 | 45 | 298,390 | 224,546 |
2022-09-01 | 0.5 | 10 | 20 | 65,592 | 101,544 |
2022-06-01 | 0.3125 | 5 | 16 | 27,525 | 82,209 |
2022-03-01 | 0.3158 | 6 | 19 | 41,025 | 105,357 |
2021-12-01 | 0.9655 | 28 | 29 | 226,504 | 219,811 |
2021-09-01 | 0.5833 | 7 | 12 | 52,464 | 93,665 |
2021-06-01 | 0.25 | 2 | 8 | 16,000 | 37,425 |
2021-03-01 | 0.5714 | 4 | 7 | 13,526 | 11,478 |
2020-12-01 | 0.8148 | 22 | 27 | 273,362 | 166,060 |
2020-09-01 | 0.6 | 6 | 10 | 39,393 | 38,819 |
2020-06-01 | 0.3636 | 4 | 11 | 22,417 | 38,207 |
2020-03-01 | 0.3333 | 5 | 15 | 27,515 | 71,763 |
2019-12-01 | 0.6327 | 31 | 49 | 480,944 | 299,504 |
2019-09-01 | 0.48 | 12 | 25 | 72,525 | 105,609 |
2019-06-01 | 0.4571 | 16 | 35 | 115,253 | 213,777 |
2019-03-01 | 0.4583 | 11 | 24 | 50,121 | 96,244 |
2018-12-01 | 0.7143 | 25 | 35 | 507,185 | 208,121 |
2018-09-01 | 1.1667 | 7 | 6 | 55,244 | 16,860 |
2018-06-01 | 0.6154 | 8 | 13 | 69,889 | 134,512 |
2018-03-01 | 0.3636 | 4 | 11 | 34,364 | 75,613 |
2017-12-01 | 0.7381 | 31 | 42 | 518,203 | 496,775 |
2017-09-01 | 0.7222 | 13 | 18 | 225,966 | 215,265 |
2017-06-01 | 0.6316 | 12 | 19 | 229,147 | 389,807 |
2017-03-01 | 0.4706 | 8 | 17 | 107,498 | 239,996 |
2016-12-01 | 0.6364 | 21 | 33 | 406,410 | 288,651 |
2016-09-01 | 0.64 | 16 | 25 | 264,512 | 407,732 |
2016-06-01 | 0.4737 | 9 | 19 | 95,925 | 211,850 |
2016-03-01 | 0.4545 | 15 | 33 | 189,539 | 412,787 |
2015-12-01 | 0.4717 | 25 | 53 | 507,728 | 336,004 |
2015-09-01 | 0.5588 | 19 | 34 | 312,252 | 401,464 |
2015-06-01 | 0.4286 | 15 | 35 | 167,924 | 409,348 |
2015-03-01 | 0.5581 | 24 | 43 | 585,365 | 769,482 |
2014-12-01 | 0.5111 | 23 | 45 | 457,305 | 711,670 |
2014-09-01 | 0.5135 | 19 | 37 | 399,116 | 276,215 |
2014-06-01 | 0.5556 | 20 | 36 | 408,829 | 520,729 |
2014-03-01 | 0.4545 | 10 | 22 | 104,114 | 460,114 |
2013-12-01 | 0.4444 | 20 | 45 | 235,879 | 436,783 |
2013-09-01 | 0.8 | 16 | 20 | 318,947 | 438,103 |
2013-06-01 | 0.4138 | 12 | 29 | 245,500 | 587,567 |
2013-03-01 | 0.619 | 13 | 21 | 782,833 | 1,150,430 |
2012-12-01 | 0.5806 | 18 | 31 | 385,856 | 357,084 |
2012-09-01 | 0.6667 | 20 | 30 | 616,138 | 996,894 |
2012-06-01 | 0.5 | 9 | 18 | 371,789 | 756,037 |
2012-03-01 | 0.5833 | 7 | 12 | 232,500 | 431,000 |
2011-12-01 | 0.6774 | 21 | 31 | 882,932 | 621,173 |
2011-09-01 | 1.2222 | 11 | 9 | 390,745 | 663,997 |
2011-06-01 | 0.5 | 4 | 8 | 163,000 | 185,000 |
2011-03-01 | 0.5909 | 13 | 22 | 271,090 | 471,680 |
2010-12-01 | 0.6429 | 36 | 56 | 1,622,480 | 1,413,131 |
2010-09-01 | 0.8889 | 16 | 18 | 298,571 | 320,000 |
2010-06-01 | 0.4857 | 17 | 35 | 213,600 | 626,383 |
2010-03-01 | 0.3714 | 13 | 35 | 196,480 | 454,360 |
2009-12-01 | 0.4615 | 18 | 39 | 500,877 | 725,763 |
2009-09-01 | 0.3125 | 10 | 32 | 114,000 | 259,500 |
2009-06-01 | 0.3333 | 3 | 9 | 20,666 | 51,332 |
2009-03-01 | 0.3636 | 8 | 22 | 96,385 | 164,691 |
2008-12-01 | 1.5714 | 11 | 7 | 618,000 | 56,000 |
2008-09-01 | 0.5 | 8 | 16 | 71,486 | 155,852 |
2008-06-01 | 0.5385 | 7 | 13 | 58,820 | 81,002 |
2007-12-01 | 0.6875 | 11 | 16 | 576,000 | 428,675 |
2007-09-01 | 0.2857 | 2 | 7 | 56,000 | 212,500 |
2007-06-01 | 0.2857 | 2 | 7 | 5,650 | 29,650 |
2007-03-01 | 0.2973 | 11 | 37 | 179,694 | 412,294 |
2006-12-01 | 0.9474 | 18 | 19 | 484,350 | 379,241 |
2006-09-01 | 4.5 | 9 | 2 | 146,000 | 64,696 |
2006-06-01 | 0.5333 | 8 | 15 | 128,850 | 239,315 |
2006-03-01 | 0.7857 | 11 | 14 | 418,180 | 274,075 |
2005-12-01 | 0.375 | 6 | 16 | 96,286 | 230,572 |
2005-09-01 | 0.4286 | 9 | 21 | 107,000 | 64,000 |
2005-06-01 | 0.1429 | 3 | 21 | 32,000 | 94,000 |
2005-03-01 | 0.4516 | 14 | 31 | 219,000 | 196,000 |
2004-12-01 | 0.2941 | 10 | 34 | 74,108 | 185,900 |
2004-09-01 | 0.3077 | 12 | 39 | 150,600 | 128,200 |
2004-06-01 | 0.0909 | 3 | 33 | 18,600 | 113,200 |
2004-03-01 | 0.0732 | 3 | 41 | 22,400 | 231,467 |
2003-12-01 | 0.2286 | 8 | 35 | 106,974 | 124,613 |
2003-09-01 | 0.2778 | 15 | 54 | 159,600 | 306,550 |
2003-06-01 | 0.125 | 1 | 8 | 15,000 | 85,700 |
ResMed Notable Stakeholders
A ResMed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ResMed often face trade-offs trying to please all of them. ResMed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ResMed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
AM BE | Chair Founder | Profile | |
Michael Farrell | Chief Executive Officer, Director | Profile | |
Peter Farrell | Non-Executive Chairman of the Board | Profile | |
Bobby Ghoshal | Chief Technology Officer, President - SaaS business | Profile | |
Jim Hollingshead | President – sleep and respiratory care business | Profile | |
Richard McHale | President – Respiratory Care Business | Profile | |
Robert Douglas | President, Chief Operating Officer | Profile | |
Raj Sodhi | President – Software as a Service (SaaS) Business and CTO | Profile | |
Brett Sandercock | CFO and Principal Accounting Officer | Profile | |
Urvashi Tyagi | Chief Technology Officer | Profile | |
Ronald Taylor | Lead Independent Director | Profile | |
Harjit Gill | Independent Director | Profile | |
Carol Burt | Independent Director | Profile | |
Jan Witte | Independent Director | Profile | |
Karen Drexler | Independent Director | Profile | |
Richard Sulpizio | Independent Director | Profile | |
Michael Rider | Chief Secretary | Profile | |
Vered Keisar | Chief Officer | Profile | |
Carlos MD | Chief Officer | Profile | |
Kaushik Ghoshal | Chief SaaS | Profile | |
Michael Fliss | Chief Officer | Profile | |
Rajwant Sodhi | President – Software as a Service Business (SaaS) | Profile | |
BE MBA | CEO Director | Profile | |
AM AM | Founder Chairman | Profile | |
Constance Bienfait | Director Relations | Profile | |
Hemanth Reddy | Chief Officer | Profile | |
Dawn Haake | Chief Officer | Profile | |
Justin Leong | President – Asia and Latin America | Profile | |
YvonneKatrin Pucknat | Chief Officer | Profile | |
Amy Wakeham | VP Communications | Profile | |
David Pendarvis | Chief Administrative Officer, Global General Counsel, Secretary | Profile | |
Jim Ellis | Chief Officer | Profile | |
Alastair Robertson | Chief Officer | Profile | |
Todd Friedman | Chief Officer | Profile |
About ResMed Management Performance
The success or failure of an entity such as ResMed Inc often depends on how effective the management is. ResMed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ResMed management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ResMed management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.29 | 0.30 | |
Return On Capital Employed | 0.22 | 0.14 | |
Return On Assets | 0.15 | 0.10 | |
Return On Equity | 0.21 | 0.14 |
Please note, the presentation of ResMed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ResMed's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ResMed's management manipulating its earnings.
ResMed Workforce Analysis
Traditionally, organizations such as ResMed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ResMed within its industry.ResMed Manpower Efficiency
Return on ResMed Manpower
Revenue Per Employee | 137.8M | |
Revenue Per Executive | 137.8M | |
Net Income Per Employee | 30M | |
Net Income Per Executive | 30M | |
Working Capital Per Employee | 42.6M | |
Working Capital Per Executive | 42.6M |
Complementary Tools for ResMed Stock analysis
When running ResMed's price analysis, check to measure ResMed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ResMed is operating at the current time. Most of ResMed's value examination focuses on studying past and present price action to predict the probability of ResMed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ResMed's price. Additionally, you may evaluate how the addition of ResMed to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |